News

Filter

Current filters:

OncologyJanssen

1 to 9 of 34 results

AstraZeneca, Pharmacyclics and Janssen team up on Imbruvica and MEDI4736 combination trial

AstraZeneca, Pharmacyclics and Janssen team up on Imbruvica and MEDI4736 combination trial

04-11-2014

Anglo-Swedish drug major AstraZeneca and US health care giant Johnson & Johnson’s Europe-based subsidiary…

AstraZenecaBiotechnologyImbruvicaJanssenMEDI4736OncologyPharmacyclicsResearchUK

Genmab gets latest milestone in daratumumab Janssen collaboration

Genmab gets latest milestone in daratumumab Janssen collaboration

24-10-2014

Danish biotech company Genmab has reached the fourth milestone in its daratumumab collaboration with…

daratumumabDenmarkGenmabJanssenOncologyPharmaceuticalResearch

Bristol-Myers Squibb, Pharmacyclics and Janssen team up to test Opdivo and Imbruvica combination

Bristol-Myers Squibb, Pharmacyclics and Janssen team up to test Opdivo and Imbruvica combination

13-10-2014

US drug major Bristol-Myers Squibb, US-based biopharma company Pharmacyclics and Janssen Research and…

BiotechnologyBristol-Myers SquibbEuropeImbruvicaJanssenOncologyOpdivoPharmacyclics

ESMO 2014: Novartis’ Afinitor; and Janssen’s Zytiga

ESMO 2014: Novartis’ Afinitor; and Janssen’s Zytiga

28-09-2014

Swiss pharma major Novartis on Saturday presented final results on overall survival (OS) from a Phase…

AfinitorJanssenJohnson & JohnsonNovartisOncologyPharmaceuticalResearchSpainZytiga

NICE says benefit of prostate cancer drug Zytiga does not justify price

NICE says benefit of prostate cancer drug Zytiga does not justify price

15-08-2014

The UK’s National Institute for Health and Care Excellence (NICE) has not recommended Zytiga (abiraterone)…

AbirateroneAndrew DillonJanssenOncologyPharmaceuticalRegulationUKZytiga

Negative NICE draft guidance on Janssen’s Zytiga for prostate cancer

Negative NICE draft guidance on Janssen’s Zytiga for prostate cancer

14-05-2014

In draft guidance published this morning, the UK drugs watchdog the National Institute for Health and…

JanssenJohnson & JohnsonOncologyPharmaceuticalPricingRegulationUKZytiga

UK NICE backs Janssen’s Velcade for multiple myeloma

UK NICE backs Janssen’s Velcade for multiple myeloma

21-03-2014

In new draft guidance published today, UK drugs watchdog the National Institute for Health and Care Excellence…

JanssenJohnson & JohnsonNorthern EuropeOncologyPharmaceuticalPricingRegulationUKVelcade

1 to 9 of 34 results

COMPANY SPOTLIGHT

Menarini

Back to top